With Little Product Overlap, Pfizer/Wyeth Commercial Synergies Are Subtle
Commercial synergies clearly are not driving Pfizer's pending acquisition of Wyeth. The companies have said that their marketed products are largely complementary with little overlap, and analysts agree
You may also be interested in...
The year 2008 won't go down as the bleakest for new molecular entity drug launches. After all, FDA did approve 24 novel biologics and new molecular entities in 2008, more than in any of the three years prior
At least one class of therapies - anti-tumor necrosis factors - is booming, even in the midst of one of the worst years financially for the pharmaceutical industry
In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care and emerging markets